← Back to Search
Do We Need A Revised Staging System For Malignant Pleural Mesothelioma? Analysis Of The IASLC Database.
V. Rusch, D. Giroux
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
INTRODUCTION A number of staging systems have been proposed for malignant pleural mesothelioma (MPM) in the past, but few have utilized a TNM (tumor, node, metastasis) system. The International Association for the Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG) previously developed a TNM-staging system which has been accepted by the International Union Against Cancer (UICC) and the American Joint Commission on Cancer (AJCC). The present study examines this staging system by analysing the updated IASLC database for patients with MPM. METHODS De-identified data from participating centres dated from 1995 to 2009 were submitted to the IASLC Statistical Center. Surgical procedures included those with a curative or palliative intent. Survival was measured from the date of pathologic diagnosis to the most recent contact or death. Endpoints included overall survival and analysis of potential prognostic factors. RESULTS Data was available for 3,101 patients from 15 centers, mostly from North America and Europe. After a median follow-up of 15 months, a number of clinicopathological and treatment-related prognostic factors were found to significantly influence overall survival. These included overall tumor stage based on the proposed TNM staging system, T category, N category, tumor histology, gender, age, and type of operation. CONCLUSIONS The IASLC database represents the largest, multicenter and international database on MPM to date. Analyses demonstrate that the proposed TNM staging system effectively distinguishes the T and N categories, but also highlight areas for potential revision in the future.
This paper references
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma--institutional review and current update.
C. Cao (2011)
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
P. Goldstraw (2007)
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
122 Risk factors for major complications after extrapleural pneumonectomy
M. Perrot (2006)
AJCC Cancer Staging Manual
M. B. Amin (2002)
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
A. Nakas (2010)
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Do we need a revised staging system for malignant pleural mesothelioma ? Analysis of the IASLC database
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
[International Union Against Cancer].
C. Sherman (1952)
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
TNM Classification of Malignant Tumours
L. Sobin (1987)
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
T. Yamanaka (2009)
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
This paper is referenced by
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
Clinical diagnosis of malignant pleural mesothelioma.
A. Bianco (2018)
Preoperative evaluation of six-minute walk test in patients with malignant pleural mesothelioma
M. Nagaya (2017)
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
W. Vigneswaran (2017)
WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience.
S. Qadri (2014)
Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI.
D. Murphy (2019)
Modern Surgical Techniques in Malignant Pleural Mesothelioma
Y. Kahya (2016)
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
J. Remon (2020)
Extrapleural Pneumonectomy A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma
S. Qadri (2015)
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Y. Kinoshita (2018)
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
Características clínicas, espirométricas y radiológicas de los trabajadores expuestos al amianto en el área sanitaria de Ferrol: experiencia de una consulta monográfica de vigilancia post-ocupacional : Febrero 2002-Febrero 2009
Diego Roza (2015)
The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.
A. Sharkey (2016)
The eighth TNM classification for malignant pleural mesothelioma.
L. Berzenji (2018)
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
A. Nakas (2014)
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
D. Mahvi (2018)
Multi-modality Imaging of Pleural and Peritoneal Disease
J. Cunningham (2018)
Clinical and Radiologic Features
A. Roden (2015)
Malignant pleural mesothelioma.
D. Ettinger (2012)
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
O. Abdel-Rahman (2017)
Advances in mesothelioma imaging and implications for surgical management
K. Blyth (2018)
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Diana Y. Kircheva (2016)
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M. A. Bedirhan (2013)
Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.
A. Nicholson (2018)
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study
S. Tsim (2016)
Overview of treatment related complications in malignant pleural mesothelioma.
D. Murphy (2017)
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)See more